Skip to main content
Premium Trial:

Request an Annual Quote

Visible Genetics Completes $7 Million Private Financing

Premium

TORONTO--Visible Genetics announced the completion of a $7 million debt financing with a group of private and institutional investors. The maker and marketer of high-performance automated DNA sequencing systems here said the funds will be used for expansion of its international sales and marketing operations, research and development, and for general working capital purposes. The company will now focus on further expanding the company's presence in the HIV, HPV, and HLA genotyping areas, as well as work to develop new applications for its technologies and products, President John Stevens said.

The loan bears interest at an annual rate of 10 percent and is due in 12 months. In addition, the investors received 420,000 warrants to purchase an equivalent number of common shares until April 29, 2003 at $10 per share.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.